ArticleEndocrine2025
Lipocalin-2 levels in children with idiopathic short stature.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIdiopathic short stature (ISS) is defined as height below − 2 standard deviation scores (SDS) without identifiable causes. Lipocalin-2 (LCN2), a protein involved in inflammation and growth plate regulation, was hypothesized to be elevated in ISS, potentially disrupting growth via inflammatory or non-inflammatory mechanisms at the growth plate. This study aimed to compare serum LCN2 levels in children with ISS versus healthy controls and assess LCN2 as a biomarker for growth failure.
methodsIn a case-control study (July 2023–January 2025), serum LCN2 levels were measured using ELISA in 28 pre-pubertal children with ISS (height ≤ 3rd percentile, normal growth hormone response) and 30 healthy controls (height ≥ 25th percentile). Height SDS, body mass index (BMI) SDS, and insulin-like growth factor-I (IGF-I) SDS were assessed.
resultsSerum LCN2 levels were significantly lower in the ISS group (80.48 ± 20.78 ng/mL) compared to controls (95.37 ± 22.70 ng/mL; p = 0.012). Height SDS positively correlated with LCN2 levels (r = 0.264, p = 0.045), but no correlations were found with age, BMI SDS, or IGF-I SDS. BMI SDS was lower in the ISS than in the control group (-0.32 ± 0.81 vs. 0.35 ± 1.21; p = 0.015).
conclusionsSerum LCN2 levels may be lower in children with ISS than in children with normal stature. Future studies should attempt to elucidate the possible role of LCN2 in regulation of linear growth.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.